Summit Therapeutics' Lung Cancer Drug Outperforms Merck's Keytruda in Trial

Phase 3 trial data shows ivonescimab extends progression-free survival significantly compared to Keytruda.

Ivonescimab nearly doubled progression-free survival in non-small cell lung cancer patients.
Summit shares surged 37% following the release of the trial results.
Merck's Keytruda, despite being outperformed, is not immediately threatened in the market.
Analysts highlight that Summit's drug is still years away from market availability.
The trial involved nearly 400 patients and was conducted by Chinese company Akeso.